(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.32%) $79.20
(0.15%) $2.04
(0.13%) $2 312.60
(0.28%) $26.91
(0.11%) $963.70
(-0.02%) $0.932
(-0.06%) $10.99
(-0.06%) $0.797
(-0.01%) $91.12
-0.47% $ 0.995
Live Chart Being Loaded With Signals
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer...
Stats | |
---|---|
Dzisiejszy wolumen | 1.25M |
Średni wolumen | 126 338 |
Kapitalizacja rynkowa | 20.90M |
EPS | $0 ( 2024-04-04 ) |
Następna data zysków | ( $-0.230 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.040 |
ATR14 | $0.0140 (1.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Guerin Mark Patrick | Buy | 8 666 | Common Stock |
2024-03-14 | Guerin Mark Patrick | Sell | 2 591 | Common Stock |
2024-03-13 | Guerin Mark Patrick | Sell | 8 666 | Restricted Stock Units |
2024-03-13 | Fruchtman Steven M | Buy | 23 111 | Common Stock |
2024-03-14 | Fruchtman Steven M | Sell | 8 727 | Common Stock |
INSIDER POWER |
---|
75.82 |
Last 95 transactions |
Buy: 2 889 396 | Sell: 191 603 |
Wolumen Korelacja
Onconova Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Onconova Therapeutics Inc Korelacja - Waluta/Towar
Onconova Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $226 000 |
Zysk brutto: | $226.00B (100 000 000.00 %) |
EPS: | $-0.900 |
FY | 2023 |
Przychody: | $226 000 |
Zysk brutto: | $226.00B (100 000 000.00 %) |
EPS: | $-0.900 |
FY | 2022 |
Przychody: | $226 000 |
Zysk brutto: | $212 000 (93.81 %) |
EPS: | $-0.880 |
FY | 2021 |
Przychody: | $226 000 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.960 |
Financial Reports:
No articles found.
Onconova Therapeutics Inc
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej